AbCellera Biologics Investor Relations Material
Latest events
Q2 2024
AbCellera Biologics
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from AbCellera Biologics Inc
Access all reports
AbCellera Biologics, Inc. operates as a biotechnology company. The Company offers antibody discovery platform that accelerates the design of therapeutic antibodies and helps researchers discover new treatments for people with cancer or Alzheimer's disease. The company's platform discovers and characterizes fully human antibodies from natural immune responses in order to provide insights into how best to stimulate the human immune system.
Key slides for AbCellera Biologics Inc
Q1 2024
AbCellera Biologics Inc
Q1 2024
AbCellera Biologics Inc
Latest articles
Cristiano Amon: Qualcomm's 5G Specialist CEO
Cristiano Amon, Qualcomm CEO, has spent two decades at the company while taking on several roles, developing both technical and business expertise.
16 Sep 2024
Qualcomm: Quality Communication and Semiconductor Innovation
Founded in 1985, Qualcomm has transformed the digital communication industry with CDMA technology and its advanced semiconductor business.
13 Sep 2024
Strong Opinions, Loosely Held: Pontus Dackmo on Flexibility and Market Psychology
After a two-decade career in finance, Pontus Dackmo co-founded Protean Funds Scandinavia in 2022, where he now serves as CEO and Investment Manager.
4 Sep 2024
Ticker symbol
ABCL
Country
🇺🇸 United States